FluidForm Bio Sets New Standard With CHIPS: Bioprinted, Vascularized, Insulin-Producing Tissue Breakthrough

FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes,  today announced the publication of a groundbreaking study in Science Advances introducing CHIPS—Collagen-based High-resolution Internally Perfusable Scaffolds. The breakthrough platform is designed to engineer fully biologic, vascularized, and insulin-producing tissues using 3D bioprinting technology.

The research, led by Dr. Adam Feinberg and his team at Carnegie Mellon University, showcases the power of CHIPS in creating centimeter-scale tissue constructs that closely replicate the function and structure of native organs.

“CHIPS represent the next generation of tissue scaffolding,” said Andrew Hudson, PhD, Co-Founder of FluidForm Bio and co-author of the study. “They enable not just structure, but function—supporting dynamic perfusion, vascularization, and even glucose-stimulated insulin secretion in engineered tissue constructs. This is the kind of platform our therapeutic programs require.”

The innovation lies in combining native extracellular matrix materials such as collagen and fibrin with vascular and endocrine cells, including insulin-secreting MIN6 beta-like cells. The result: a perfusable, biologically active pancreatic-like tissue that responds to glucose and secretes insulin, with a performance surpassing traditional tissue engineering methods.

“These results validate FRESH as the enabling technology not only for research but for our ongoing clinical translation,” said Dr. Adam Feinberg, Co-Founder and Chief Technology Officer of FluidForm Bio. “The constructs described in this paper are essentially blueprints for what we’re building at FluidForm—fully cellularized, vascularized tissues for subcutaneous implantation and therapeutic function.”

CHIPS serves as a critical evolution of FluidForm’s FRESH™ 3D bioprinting technology, forming a bridge from lab research to therapeutic application. The tissue constructs demonstrated sustained insulin output, vascular network formation, and significant cell migration under perfusion conditions—key factors in replicating functional organ systems.

The study strengthens FluidForm Bio’s islet cell replacement therapy pipeline, which utilizes FRESH printing to generate implantable scaffolds that safeguard islet viability, support vascular integration, and aim to deliver long-term glycemic control without systemic immunosuppression. In preclinical models, the company has already achieved sustained normoglycemia for over five months.

This scientific milestone coincides with FluidForm Bio’s ongoing equity crowdfunding campaign on StartEngine, allowing the public to invest in the future of regenerative medicine and the company's mission to transform treatment for chronic conditions.